MAPK3 and cancer: Preclinical studies showed efficient inhibition of phosphorylation of ERK1 and ERK2, which correlates with potent growth inhibition in cancer cell lines with mutant BRAF or RAS with elevated phosphorylation of MEK1 and MEK2 [3, 4, 26, 27].